The incidence of Hepatitis C along with other socially significant diseases is progressing yearly in Kazakhstan (4.6-fold increase over the past ten years). Within this project UNDP will support capacity development of “SK-Pharmacy”, LLP in the field of procurement of medicines, health products and medical equipment, required for treatment of socially significant diseases, including Hepatitis C.

Planned procurement activities:

• Hep C medicine Sofosbuvir for 18,460 patients;
• Hep C medicine Daklatasvir for 18,460 patients;

Procurement activities 2019:

• Hep C medicine Sofosbuvir for 2,731 patients;
• Hep C medicine Daklatasvir for 2,731 patients;

Potential procurement activities:

• Adalimumab (rheumatoid arthritis) - 929 pre-filled syringes;
• Dolutegravir 50 mg (ARV) - 41.951 packs;
• Additional order for Sofosbuvir/Daclatasvir

UNDP expertise:

 At international level:

• Multi-country expertise in implementation of procurement projects via competitive processes in a wide range of settings;
• Efficient and competitive international economy of scale through wide-scale procurement process (pooling the demands of multiple UNDP Cos, procurement planning, obtaining significant discounts on products for a whole volume of globally supplied goods).

At national level:

• Project administration, including financial and administrative issues;
• Support to capacity development of National Partner in the field of procurement of medicines, health products and medical equipment;

• Conducting competitive bidding processes at international and national levels;
• Placement of the orders for goods, freight and insurance;
• Procurement of quality medical products from reliable suppliers at lowest available prices;

Project expected results:

• Provision of population of the Republic of Kazakhstan with the high-quality medical products;
• Capacity building support of Kazakhstani medical facilities by equipping them with innovative diagnostic technologies and consumables;
• Increased level of efficiency and accessibility of treatment within the framework of guaranteed volume of free medical care (ГОБМП);
• Increased capacity potential of national partners in the procurement area;
• Increased capacities of medical facilities and health care institutions.

Project beneficiaries:

Patients with potential and diagnosed Hepatitis C and other socially significant diseases

Project’s geography:

Whole territory of the

Republic of Kazakhstan

Project duration:

2018-2020

Total budget:

$4,399,714.69

Donors/Partners:

• SK-Pharmacy, LLP – $4,399,714.69
• Ministry of Health of Kazakhstan